NASDAQ:COLL Collegium Pharmaceutical (COLL) Stock Price, News & Analysis → Your Money is Not Safe (From American Alternative) (Ad) Free COLL Stock Alerts $38.82 -2.09 (-5.11%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$38.59▼$40.9550-Day Range$31.76▼$40.9152-Week Range$20.83▼$40.95Volume613,299 shsAverage Volume506,933 shsMarket Capitalization$1.24 billionP/E Ratio32.90Dividend YieldN/APrice Target$39.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Collegium Pharmaceutical alerts: Email Address Collegium Pharmaceutical MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.60 Rating ScoreUpside/Downside0.5% Upside$39.00 Price TargetShort InterestBearish22.92% of Float Sold ShortDividend StrengthN/ASustainability-2.78Upright™ Environmental ScoreNews Sentiment0.45Based on 7 Articles This WeekInsider TradingSelling Shares$760,517 Sold Last QuarterProj. Earnings Growth9.59%From $5.63 to $6.17 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.16 out of 5 starsMedical Sector556th out of 939 stocksPharmaceutical Preparations Industry265th out of 444 stocks 1.3 Analyst's Opinion Consensus RatingCollegium Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $39.00, Collegium Pharmaceutical has a forecasted upside of 0.5% from its current price of $38.82.Amount of Analyst CoverageCollegium Pharmaceutical has only been the subject of 4 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted22.92% of the float of Collegium Pharmaceutical has been sold short.Short Interest Ratio / Days to CoverCollegium Pharmaceutical has a short interest ratio ("days to cover") of 15.7, which indicates bearish sentiment.Change versus previous monthShort interest in Collegium Pharmaceutical has recently increased by 4.32%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCollegium Pharmaceutical does not currently pay a dividend.Dividend GrowthCollegium Pharmaceutical does not have a long track record of dividend growth. Previous Next 3.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCollegium Pharmaceutical has received a 26.40% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Tapendatol" and "Oxycodone" products. See details.Environmental SustainabilityThe Environmental Impact score for Collegium Pharmaceutical is -2.78. Previous Next 2.5 News and Social Media Coverage News SentimentCollegium Pharmaceutical has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Collegium Pharmaceutical this week, compared to 3 articles on an average week.Search InterestOnly 3 people have searched for COLL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows13 people have added Collegium Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is an increase of 550% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Collegium Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $760,517.00 in company stock.Percentage Held by InsidersOnly 3.69% of the stock of Collegium Pharmaceutical is held by insiders. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Collegium Pharmaceutical are expected to grow by 9.59% in the coming year, from $5.63 to $6.17 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Collegium Pharmaceutical is 32.90, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 137.51.Price to Earnings Ratio vs. SectorThe P/E ratio of Collegium Pharmaceutical is 32.90, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 191.25.Price to Book Value per Share RatioCollegium Pharmaceutical has a P/B Ratio of 6.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyElon Musk’s warning to AmericaUrgent Presidential Warning: Coming election shock could decimate millions of Americans, wiping out their savings and way of life.Go here to learn how to protect wealth and family. About Collegium Pharmaceutical Stock (NASDAQ:COLL)Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.Read More COLL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart COLL Stock News HeadlinesMarch 29, 2024 | americanbankingnews.comCollegium Pharmaceutical (NASDAQ:COLL) Downgraded by StockNews.comMarch 24, 2024 | americanbankingnews.comCollegium Pharmaceutical (NASDAQ:COLL) Reaches New 12-Month High at $39.96March 29, 2024 | American Alternative (Ad)Your Money is Not SafeBiden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…March 23, 2024 | wsj.comCollegium Pharmaceutical Inc.March 22, 2024 | americanbankingnews.comCollegium Pharmaceutical (NASDAQ:COLL) Upgraded to "Strong-Buy" by StockNews.comMarch 22, 2024 | americanbankingnews.comAnalysts Set Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Target Price at $39.00March 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for KalVista Pharmaceuticals on Strong Phase 3 Results and Solid Financial PositionMarch 5, 2024 | finance.yahoo.comCOLL Mar 2024 50.000 callMarch 29, 2024 | American Alternative (Ad)Your Money is Not SafeBiden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…March 4, 2024 | insidermonkey.com5 Best Small Cap Pharma Stocks to Invest InFebruary 29, 2024 | finance.yahoo.comInsider Sell: EVP & Chief Commercial Officer Scott Dreyer Sells 10,000 Shares of Collegium ...February 28, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Tarsus Pharmaceuticals (TARS), Protagonist Therapeutics (PTGX) and Viridian Therapeutics (VRDN)February 27, 2024 | finance.yahoo.comThis Unsung Pharmaceutical Stock In The IBD 50 Hit A Buy Zone. Here's Why.February 26, 2024 | seekingalpha.comCollegium Pharmaceutical Q4: The Beat Goes OnFebruary 25, 2024 | msn.comNasdaq Closes In On All-Time High; Carvana Spikes On Earnings While Nvidia Vaults Above 800February 24, 2024 | finance.yahoo.comCollegium Pharmaceutical Full Year 2023 Earnings: EPS Beats ExpectationsFebruary 23, 2024 | markets.businessinsider.comWhere Collegium Pharmaceutical Stands With AnalystsFebruary 23, 2024 | insidermonkey.comCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Q4 2023 Earnings Call TranscriptFebruary 23, 2024 | finance.yahoo.comQ4 2023 Collegium Pharmaceutical Inc Earnings CallFebruary 22, 2024 | benzinga.comRecap: Collegium Pharmaceutical Q4 EarningsFebruary 22, 2024 | finance.yahoo.comCollegium Pharmaceutical Inc Reports Record Earnings for Q4 and Full-Year 2023February 22, 2024 | seekingalpha.comCollegium Pharmaceutical, Inc. 2023 Q4 - Results - Earnings Call PresentationFebruary 22, 2024 | globenewswire.comCollegium Reports Record Fourth Quarter and Full-Year 2023 Financial ResultsFebruary 22, 2024 | benzinga.comCollegium Pharmaceutical Stock (NASDAQ:COLL), Short Interest ReportFebruary 16, 2024 | finance.yahoo.comCOLL Mar 2024 30.000 callFebruary 11, 2024 | cnn.comCollegium Pharmaceutical, Inc.February 8, 2024 | finance.yahoo.comCollegium to Report Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024See More Headlines Receive COLL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Collegium Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today3/29/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:COLL CUSIPN/A CIK1267565 Webwww.collegiumpharma.com Phone(781) 713-3699FaxN/AEmployees197Year FoundedN/APrice Target and Rating Average Stock Price Target$39.00 High Stock Price Target$40.00 Low Stock Price Target$37.00 Potential Upside/Downside+0.5%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)$1.18 Trailing P/E Ratio32.90 Forward P/E Ratio6.90 P/E GrowthN/ANet Income$48.15 million Net Margins8.50% Pretax Margin13.36% Return on Equity107.39% Return on Assets17.07% Debt Debt-to-Equity Ratio2.48 Current Ratio1.17 Quick Ratio1.10 Sales & Book Value Annual Sales$566.77 million Price / Sales2.19 Cash Flow$10.22 per share Price / Cash Flow3.80 Book Value$5.99 per share Price / Book6.48Miscellaneous Outstanding Shares31,960,000Free Float30,781,000Market Cap$1.24 billion OptionableOptionable Beta1.02 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Michael Thomas Heffernan B.S. Pharm (Age 60)R.Ph., Co-Founder & Chairman Comp: $110kMr. Joseph J. Ciaffoni (Age 52)President, CEO & Director Comp: $1.69MMs. Colleen Tupper (Age 48)Executive VP & CFO Comp: $848.29kMs. Shirley R. Kuhlmann (Age 40)Executive VP, General Counsel, Chief Administrative Officer & Secretary Comp: $842.9kMr. Scott Dreyer (Age 52)Executive VP & Chief Commercial Officer Comp: $746.58kDr. Thomas B. Smith FAAFP (Age 63)M.D., Executive VP & Chief Medical Officer Comp: $692.91kDr. Christopher Shayne James M.D.Vice President of Investor RelationsMr. Bart J. DunnExecutive Vice President of Strategy & Corporate DevelopmentMr. Scott SudduthHead of Technical OperationsMore ExecutivesKey CompetitorsVerona PharmaNASDAQ:VRNABelite BioNASDAQ:BLTEIronwood PharmaceuticalsNASDAQ:IRWDXencorNASDAQ:XNCRPacira BioSciencesNASDAQ:PCRXView All CompetitorsInsiders & InstitutionsHighPoint Advisor Group LLCBought 16,685 shares on 3/26/2024Ownership: 0.052%Vanguard Group Inc.Sold 26,310 shares on 3/11/2024Ownership: 7.237%Eventide Asset Management LLCSold 856 shares on 2/20/2024Ownership: 8.066%Price T Rowe Associates Inc. MDBought 766 shares on 2/16/2024Ownership: 0.088%West Tower Group LLCBought 450 shares on 2/15/2024Ownership: 0.003%View All Insider TransactionsView All Institutional Transactions COLL Stock Analysis - Frequently Asked Questions Should I buy or sell Collegium Pharmaceutical stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Collegium Pharmaceutical in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" COLL shares. View COLL analyst ratings or view top-rated stocks. What is Collegium Pharmaceutical's stock price target for 2024? 5 brokerages have issued 12-month price targets for Collegium Pharmaceutical's stock. Their COLL share price targets range from $37.00 to $40.00. On average, they expect the company's stock price to reach $39.00 in the next twelve months. This suggests a possible upside of 0.5% from the stock's current price. View analysts price targets for COLL or view top-rated stocks among Wall Street analysts. How have COLL shares performed in 2024? Collegium Pharmaceutical's stock was trading at $30.78 at the beginning of the year. Since then, COLL stock has increased by 26.1% and is now trading at $38.82. View the best growth stocks for 2024 here. When is Collegium Pharmaceutical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our COLL earnings forecast. How were Collegium Pharmaceutical's earnings last quarter? Collegium Pharmaceutical, Inc. (NASDAQ:COLL) announced its quarterly earnings results on Thursday, February, 22nd. The specialty pharmaceutical company reported $1.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.20 by $0.25. The specialty pharmaceutical company had revenue of $149.75 million for the quarter, compared to analysts' expectations of $147.66 million. Collegium Pharmaceutical had a trailing twelve-month return on equity of 107.39% and a net margin of 8.50%. What ETFs hold Collegium Pharmaceutical's stock? ETFs with the largest weight of Collegium Pharmaceutical (NASDAQ:COLL) stock in their portfolio include First Trust Dow Jones Select Microcap Index Fund (FDM), Inspire Fidelis Multi Factor ETF (FDLS), Pacer US Small Cap Cash Cows Growth Leaders ETF (CAFG), SPDR S&P Pharmaceuticals ETF (XPH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).iShares U.S. Pharmaceuticals ETF (IHE). What guidance has Collegium Pharmaceutical issued on next quarter's earnings? Collegium Pharmaceutical updated its FY 2024 earnings guidance on Thursday, February, 22nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $580.0 million-$595.0 million, compared to the consensus revenue estimate of $583.5 million. What is Joseph Ciaffoni's approval rating as Collegium Pharmaceutical's CEO? 6 employees have rated Collegium Pharmaceutical Chief Executive Officer Joseph Ciaffoni on Glassdoor.com. Joseph Ciaffoni has an approval rating of 68% among the company's employees. What other stocks do shareholders of Collegium Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Collegium Pharmaceutical investors own include Galapagos (GLPG), NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Cara Therapeutics (CARA), Pfizer (PFE), Bausch Health Companies (BHC), Gilead Sciences (GILD) and GW Pharmaceuticals (GWPH). When did Collegium Pharmaceutical IPO? Collegium Pharmaceutical (COLL) raised $75 million in an initial public offering (IPO) on Thursday, May 7th 2015. The company issued 5,800,000 shares at $12.00-$14.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers. Who are Collegium Pharmaceutical's major shareholders? Collegium Pharmaceutical's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Rubric Capital Management LP (8.46%), Eventide Asset Management LLC (8.07%), Vanguard Group Inc. (7.09%), Vanguard Group Inc. (7.24%), Pacer Advisors Inc. (6.67%) and Principal Financial Group Inc. (4.81%). Insiders that own company stock include Colleen Tupper, Joseph Ciaffoni, Michael Thomas Heffernan, Scott Dreyer and Shirley R Kuhlmann. View institutional ownership trends. How do I buy shares of Collegium Pharmaceutical? Shares of COLL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:COLL) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 Media“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Collegium Pharmaceutical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.